Eslovènia - eslovè - Ecolab

ecolab deutschland gmbh -

Unió Europea - eslovè - EMA (European Medicines Agency)

koanaa healthcare gmbh - imatinib mesilate - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma; gastrointestinal stromal tumors - antineoplastična sredstva - imatinib koanaa is indicated for the treatment ofadult and paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. adult and paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. adult patients with relapsed or refractory ph+ all as monotherapy. adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfrα rearrangement. the effect of imatinib on the outcome of bone marrow transplantation has not been determined. imatinib koanaa is indicated forthe treatment of adult patients with kit (cd 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). the adjuvant treatment of adult patients who are at significant risk of relapse following resection of kit (cd117)-positive gist. bolniki, ki imajo nizko ali zelo nizko tveganje za ponovitev, ne bi smel imeti adjuvant treatment. the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic gist and dfsp and on recurrence-free survival in adjuvant gist. the experience with imatinib in patients with mds/mpd associated with pdgfr gene re-arrangements is very limited (see section 5. razen v novo diagnozo kronične faze cml, ni kontroliranih preskušanjih, dokazujejo kliničnih koristi ali poveča preživetje pri teh bolezni.

Unió Europea - eslovè - EMA (European Medicines Agency)

janssen-cilag international n.v.    - amivantamab - karcinom, pljučni pljuč - antineoplastična sredstva - rybrevant as monotherapy is indicated for treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating epidermal growth factor receptor (egfr) exon 20 insertion mutations, after failure of platinum-based chemotherapy.

Unió Europea - eslovè - EMA (European Medicines Agency)

vbi vaccines b.v. - površinski antigen hepatitisa b - hepatitis b - cepiva - prehevbri is indicated for active immunisation against infection caused by all known subtypes of the hepatitis b virus in adults. it can be expected that hepatitis d will also be prevented by immunisation with prehevbri as hepatitis d (caused by the delta agent) does not occur in the absence of hepatitis b infection. the use of prehevbri should be in accordance with official recommendations.

Unió Europea - eslovè - EMA (European Medicines Agency)

astrazeneca ab - tremelimumab - karcinom, pljučni pljuč - antineoplastična sredstva - tremelimumab astrazeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.

Unió Europea - eslovè - EMA (European Medicines Agency)

jazz pharmaceuticals ireland limited - crisantaspase - predkroglomerna limfoblastna levkemija limfoma - antineoplastična sredstva - enrylaze is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukaemia (all) and lymphoblastic lymphoma (lbl) in adult and paediatric patients (1 month and older) who developed hypersensitivity or silent inactivation to e. coli-derived asparaginase.

Eslovènia - eslovè - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

kapsula s podaljšanim sproščanjem, trda - hidromorfon

Eslovènia - eslovè - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

kapsula s podaljšanim sproščanjem, trda - hidromorfon

Eslovènia - eslovè - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

kapsula s podaljšanim sproščanjem, trda - hidromorfon

Unió Europea - eslovè - EMA (European Medicines Agency)

sandoz pharmaceuticals d.d. - nelarabin - predkroglomerna limfoma t-celična limfoblastna levkemija - antineoplastična sredstva - nelarabine je indiciran za zdravljenje bolnikov z t-celic acute lymphoblastic levkemijo (t-all) in t-celic lymphoblastic limfom (t-lbl), katerih bolezen ni odgovorila, ali je relapsed po zdravljenju z vsaj dvema kemoterapijo regimens. due to the small patient populations in these disease settings, the information to support these indications is based on limited data.